IMF-001

BIOLOGICAL2 trials

Sponsors

ImmunoFrontier, Inc.

Conditions

Esophageal CancerSolid Tumor

Phase 1

Safety Study of a Recombinant Protein Vaccine to Treat Esophageal Cancer

CompletedNCT01003808

ImmunoFrontier, Inc.Esophageal Cancer

Start: 2009-11-30End: 2012-12-31Updated: 2013-04-17

Study of IMF-001 in Patients With Malignancies Expressing NY-ESO-1

CompletedNCT01234012

ImmunoFrontier, Inc.Solid Tumor

Start: 2011-05-31End: 2014-03-31Updated: 2015-03-10

Related Papers

Dose-dependent effects of NY-ESO-1 protein vaccine complexed with cholesteryl pullulan (CHP-NY-ESO-1) on immune responses and survival benefits of esophageal cancer patients.

2013-10-0586 citations